Sun Pharma Gets CDSCO Panel Nod to Manufacture, Market Gabapentin for neuropathic pain
New Delhi: Pharmaceutical major Sun Pharma has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to manufacture and market Gabapentin extended released (ER) tablets 300mg/600mg for the treatment of neuroleptic pain as an additional indication.
This came after the drug major Sun Pharma Laboratories presented the proposal for the grant of manufacturing and marketing permission of Gabapentin ER tablets 300mg/600mg for the treatment of neuropathic pain as an additional indication along with the clinical trial waiver justification and clinical trial data of other countries, before the committee.
Gabapentin is an anticonvulsant medication used in the management of peripheral neuropathic pains, postherpetic neuralgia, and partial-onset seizures. Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA).
It inhibits the release of excitatory neurotransmitters, allowing for its use against pathologic neurotransmissions such as that seen in neuropathic pain and seizure disorders.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.